Showing 14,581 - 14,600 results of 35,126 for search '(( 50 ((((a decrease) OR (nn decrease))) OR (mean decrease)) ) OR ( 5 point decrease ))', query time: 1.11s Refine Results
  1. 14581

    DataSheet1_Real-World Management and Clinical Outcomes of Stroke Survivors With Atrial Fibrillation: A Population-Based Cohort in Spain.docx by Clara L. Rodríguez-Bernal (11829377)

    Published 2021
    “…Regarding temporal trends, management with OAC increased by 20%, with a decrease of 50% for APT during the study period. …”
  2. 14582

    Table_1_Initial Report of a Phase I Study of LY2510924, Idarubicin, and Cytarabine in Relapsed/Refractory Acute Myeloid Leukemia.DOCX by Prajwal Boddu (5780843)

    Published 2018
    “…Three and one complete responses were observed at dose-levels “0” and “1,” respectively; the overall response rate (ORR) was 36% (4 of 11 patients). A50% decrease in CXCR4 mean fluorescence intensity was observed in 4 of 9 patients by flow cytometry, indicating incomplete suppression of CXCR4-receptor occupancy.…”
  3. 14583

    Table_2_Effectiveness and tolerability of different therapies in preventive treatment of MOG-IgG-associated disorder: A network meta-analysis.docx by Xiaofei Wang (135107)

    Published 2022
    “…AZA, MMF, OC and RTX showed a trend to decrease ARR, but those results did not reach significant differences. …”
  4. 14584

    Table_1_Effectiveness and tolerability of different therapies in preventive treatment of MOG-IgG-associated disorder: A network meta-analysis.docx by Xiaofei Wang (135107)

    Published 2022
    “…AZA, MMF, OC and RTX showed a trend to decrease ARR, but those results did not reach significant differences. …”
  5. 14585

    Table_1_Initial Report of a Phase I Study of LY2510924, Idarubicin, and Cytarabine in Relapsed/Refractory Acute Myeloid Leukemia.DOCX by Prajwal Boddu (5780843)

    Published 2018
    “…Three and one complete responses were observed at dose-levels “0” and “1,” respectively; the overall response rate (ORR) was 36% (4 of 11 patients). A50% decrease in CXCR4 mean fluorescence intensity was observed in 4 of 9 patients by flow cytometry, indicating incomplete suppression of CXCR4-receptor occupancy.…”
  6. 14586

    Table 1_Propolis supplementation on inflammatory and oxidative stress biomarkers in adults: a systematic review and meta-analysis of randomized controlled trials.docx by Hossein Bahari (16704768)

    Published 2025
    “…This meta-analysis revealed that propolis consumption led to a significant decrease in C-reactive protein (CRP) (WMD: –1.23; 95%CI: –1.76, –0.69; p < 0.001), Interleukin-6 (IL-6) (WMD: –1.52; 95%CI: –2.10, –0.93; p < 0.001), Tumor necrosis factor-α (WMD: –1.15; 95%CI: –1.75, –0.55; p < 0.001), and Monocyte chemoattractant protein-1 (MCP-1) (WMD: –35.33; 95%CI: –50.28, –20.37; p < 0.001), and a significant increase in total antioxidant capacity (TAC) (WMD: 0.32; 95%CI: 0.12, 0.51; p = 0.001), Glutathione (GSH) (WMD: 4.71; 95%CI: 3.17, 6.25; p < 0.001), and Glutathione peroxidase (GPx) (WMD: 44.75; 95%CI: 5.10, 84.40; p = 0.02). …”
  7. 14587

    Table_6_Effectiveness and tolerability of different therapies in preventive treatment of MOG-IgG-associated disorder: A network meta-analysis.xlsx by Xiaofei Wang (135107)

    Published 2022
    “…AZA, MMF, OC and RTX showed a trend to decrease ARR, but those results did not reach significant differences. …”
  8. 14588

    Table_3_Effectiveness and tolerability of different therapies in preventive treatment of MOG-IgG-associated disorder: A network meta-analysis.docx by Xiaofei Wang (135107)

    Published 2022
    “…AZA, MMF, OC and RTX showed a trend to decrease ARR, but those results did not reach significant differences. …”
  9. 14589

    Table_4_Effectiveness and tolerability of different therapies in preventive treatment of MOG-IgG-associated disorder: A network meta-analysis.docx by Xiaofei Wang (135107)

    Published 2022
    “…AZA, MMF, OC and RTX showed a trend to decrease ARR, but those results did not reach significant differences. …”
  10. 14590
  11. 14591
  12. 14592
  13. 14593
  14. 14594
  15. 14595
  16. 14596
  17. 14597

    Prenatal Treatment of Mosaic Mice (Atp7a mo-ms) Mouse Model for Menkes Disease, with Copper Combined by Dimethyldithiocarbamate (DMDTC) by Małgorzata Lenartowicz (150659)

    Published 2012
    “…In the present study we found that prenatal treatment of <em>mosaic</em> murine fetuses throughout gestation days 7, 11, 15 and 18 with a combination of CuCl<sub>2</sub> (50 mg/kg) and dimethyldithiocarbamate (DMDTC) (280 mg/kg) leads to an increase in survival to about 76±25.3 days, whereas treatment with CuCl<sub>2</sub> alone (50 mg/kg) only leads to survival for about 21 days ±5 days. …”
  18. 14598
  19. 14599
  20. 14600